Navigation Links
Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
Date:9/8/2010

PRINCETON, N.J., Sept. 7 /PRNewswire/ -- GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer's disease (AD) and cognitively intact healthy volunteers (HVs). The primary endpoint was the efficacy of blinded assessments of flutemetamol binding to Beta-amyloid, the major constituent of amyloid plaque, which is a pathological hallmark of AD. In the study, subjects with a high probability of amyloid (27 AD patients) and a low probability of amyloid (25 healthy subjects) underwent PET imaging with flutemetamol. Five independent image readers, each blinded to the subject's clinical status, separately decided if each subject's image corresponded to normal or raised amyloid levels. The accuracy of image assessments was determined by comparing them to the subjects' clinical diagnoses. In addition, 20 subjects with a memory disorder known as mild cognitive impairment (MCI), which may represent a pre-dementia stage of AD, were enrolled and imaged with flutemetamol.

The image readers found that scans from 25 of the 27 AD patients displayed elevated flutemetamol uptake, as did 1 of 15 HVs who were older than 55 years, corresponding to a sensitivity of 93.1% and a specificity of 93.3% against their clinical diagnoses. In the group with MCI, visual inspection revealed raised binding of flutemetamol in 9 of 20 subjects. Test-retest reliability was very high when subjects underwent repeat scanning after 7 days. Additionally, comparable uptake ratios were seen when compared to 11CPIB of which flutemetamol is an analog.

"These data show that flutemetamol ex
'/>"/>

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
7. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
8. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
9. ORTHO EVRA(R) Prescribing Information Updated
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
(Date:7/28/2014)... July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, August ... www.isispharm.com How:Live on the Internet. Simply log onto ... participate during the live event, a replay of the ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. ...
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
... , , ... use of stem cells in the treatment of heart failure, ... physicians have performed the world,s first phase-one FDA-approved clinical trial ... The clinical trial is being conducted by a team of ...
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4
(Date:7/28/2014)... Top Northridge dentist , Dr. Farshid Ariz, is ... new dentist can be an intimidating experience. Many people struggle ... and worry about how they will connect with a new ... concerns and dental needs and works to ensure that each ... special coupon can help patients get the treatments they need ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... (HealthDay News) -- Following a healthy lifestyle may help ... issues, a new study indicates. Researchers suggested that ... should be educated about how their diet ... future. "These findings are important because they indicate ... have the opportunity to influence their own health outcomes," ...
(Date:7/28/2014)... Nevada (PRWEB) July 28, 2014 Mahendra ... Trivedi, hosted the Trivedi Online Workshop ‘Consciousness is Power’ ... PM (EST). During this workshop, participants from all over ... importance of making a deeper connection to their inner ... the participants explored the various advantages of raising consciousness ...
(Date:7/28/2014)... 28, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. More ... its Fort Myers campus, and the company announced that ... is to support several health-insurance clients, which have seasonal ...
Breaking Medicine News(10 mins):Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4
... Hospitals (UH) Case Medical Center is conducting the first ... "heat therapy" or local radiofrequency energy to treat premature ... to the energy produced by radio waves directed with ... a nerve. Premature ejaculation (PE) affects 20 percent ...
... Research Institute (LRI) today announced the award of 12 ... drive innovation and discover novel approaches to understand and ... diseases lupus. Awarded for the highest-ranked ... topics and multi-disciplinary approaches that mirror the heterogeneity and ...
... Institute (GHI) and Inserm (Institut National de la Sant ... for biomedical research) has discovered that a class of ... in cancer cells also kills the parasite that causes ... new strategy for combating this deadly disease. The ...
... leg ulcers is good quality nursing care and the ... University of Leeds has shown that ultrasound therapy does nothing ... contrary to what had been expected. Traditional methods of nursing ... as well, the authors conclude. "The ,healing energy, of ...
... might be required for maximum anti-tumor activity when ... studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The ... Proceedings of the National Academy of Sciences ... HER3 receptor limits the effectiveness of two classes ...
... An analysis conducted by Ohio State University cancer ... to the treatment of patients with advanced ovarian cancer ... value of various clinical strategies will be published online ... , The researchers performed a cost-effectiveness analysis looking at ...
Cached Medicine News:Health News:University Hospitals Case Medical Center testing innovative 'heat therapy' for premature ejaculation 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 3Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 4Health News:Malaria's weakest link 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 3
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
... optimal combination of performance and rapid, ... mL swinging bucket rotor. DiscoveryTMM120 SE ... to 8.3 ml, with a small ... quiet operation, rotor imbalance detection, thermo-electric ...
Medicine Products: